CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer.
Ilaria MagagnaNicolas GourdinYann KiefferMonika LicajRana MhaidlyPascale AndreAriane MorelAnne-Vincent SalomonCarine PaturelFatima Mechta-GrigoriouPublished in: Cancers (2021)
Our data support the potential clinical benefit of using both anti-CD73 and immune-checkpoint inhibitors in breast cancer patients for inhibiting CAF-S1-mediated immunosuppression and enhancing anti-tumor immune response.